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To further understanding of the genetic basis of type 2 diabetes (T2D) susceptibility, we
aggregated published meta-analyses of genome-wide association studies (GWAS) including
26,488 cases and 83,964 controls of European, East Asian, South Asian, and Mexican and
Mexican American ancestry. We observed significant excess in directional consistency of T2D
risk alleles across ancestry groups, even at SNPs demonstrating only weak evidence of
association. By following up the strongest signals of association from the trans-ethnic meta-
analysis in an additional 21,491 cases and 55,647 controls of European ancestry, we identified
seven novel T2D susceptibility loci. Furthermore, we observed considerable improvements in
fine-mapping resolution of common variant association signals at several T2D susceptibility loci.
These observations highlight the benefits of trans-ethnic GWAS for the discovery and
characterisation of complex trait loci, and emphasize an exciting opportunity to extend insight into
the genetic architecture and pathogenesis of human diseases across populations of diverse
ancestry.
The majority of GWAS of T2D susceptibility have been undertaken in populations of
European ancestry1–5, predominantly because of existing infrastructure, sample availability,
and relatively poor coverage by many of the earliest genome-wide genotyping arrays of
common genetic variation in other major ethnic groups6. However, European ancestry
populations constitute only a subset of human genetic variation, and thus are insufficient to
fully characterise T2D risk variants in other ethnic groups. Furthermore, the latest genome-
wide genotyping arrays are less biased towards Europeans, and more recent T2D GWAS
have been performed, with great success, in populations from other ancestry groups,
including East Asians7–12, South Asians13,14, Mexicans and Mexican Americans15, and
African Americans16. These studies have provided initial evidence of overlap in T2D
susceptibility loci between ancestry groups and for coincident risk alleles at lead SNPs
across diverse populations17,18. These observations are consistent with a model in which the
underlying causal variants at many of these loci are shared across ancestry groups, and thus
arose prior to human population migration out of Africa. Under such a model, we would
expect to improve power to detect novel susceptibility loci for the disease, and enhance fine-
mapping resolution of causal variants, by combining GWAS across ancestry groups through
trans-ethnic meta-analysis, because of increased sample size and differences in the structure
of linkage disequilibrium (LD) between such diverse populations6,19–21.
In this study, we aggregated published meta-analyses of GWAS in a total of 26,488 cases
and 83,964 controls from populations of European, East Asian, South Asian, and Mexican
and Mexican American ancestry5,11,13,15. T2D GWAS from populations of African
ancestry, which would be expected to provide the greatest potential for fine-mapping of
common causal variants due to less extensive LD than other ethnic groups6, were not
accessible for inclusion in our analyses. With these data, we aimed to: (i) assess the evidence
for excess concordance in the direction of effect of T2D risk alleles across ancestry groups;
(ii) identify novel T2D susceptibility loci through trans-ethnic meta-analysis and subsequent
validation in an additional 21,491 cases and 55,647 controls of European ancestry; and (iii)
evaluate the improvements in the fine-mapping resolution of common variant association
signals in established T2D susceptibility loci through trans-ethnic meta-analysis, despite the
lack of GWAS from populations of African ancestry.
RESULTS
We considered published meta-analyses of GWAS of T2D susceptibility from four major
ethnic groups (Supplementary Tables 1 and 2), undertaken by: (i) the DIAbetes Genetics
Replication and Meta-analysis (DIAGRAM) Consortium5 (European ancestry; 12,171 cases
and 56,862 controls); (ii) the Asian Genetic Epidemiology Network T2D (AGEN-T2D)
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Consortium11 (East Asian ancestry; 6,952 cases and 11,865 controls); (iii) the South Asian
T2D (SAT2D) Consortium13 (South Asian ancestry; 5,561 cases and 14,458 controls); and
(iv) the Mexican American T2D (MAT2D) Consortium15 (Mexican and Mexican American
ancestry; 1,804 cases and 779 controls). We obtained association summary statistics from
the four available ethnic-specific meta-analyses, each imputed at up to 2.5 million autosomal
SNPs from Phase II/III HapMap22,23 to provide a uniform catalogue of common genetic
variation, defined by minor allele frequency (MAF) of at least 5%, across ancestry groups
(Online Methods). These association summary statistics were then combined across
ancestry groups via trans-ethnic fixed-effects meta-analysis (Online Methods).
Directional consistency of T2D risk alleles across ancestry groups
We began by evaluating heterogeneity in allelic effects (i.e. discordance in the direction and/
or magnitude of odds-ratios) between ancestry groups at 69 established autosomal T2D
susceptibility loci. We assessed the evidence for heterogeneity at previously reported lead
SNPs on the basis of Cochran’s Q-statistic from the trans-ethnic meta-analysis (Online
Methods, Supplementary Table 3). We observed nominal evidence of heterogeneity
(Bonferroni correction, pQ<0.05/69=0.00072) at the previously reported lead SNP at just
three loci. At TCF7L2 (rs7903146, pQ=0.00055), the odds-ratio is largest in European
ancestry populations, although the risk allele has a consistent direction of effect across
ethnicities. At PEPD (rs3786897, pQ=0.00055) and KLF14 (rs13233731, pQ=0.00064),
however, the association signals are apparently specific to East Asian and European ancestry
populations, respectively, despite the fact that the reported lead SNPs are common in all
ethnic groups. We also observed that, at 52 previously reported lead SNPs passing quality
control in each of the four ethnic-specific meta-analyses, 34 showed the same direction of
effect across all ancestry groups (65.4%, compared with 12.5% expected by chance,
binomial test p<2.2×10−16). The strong evidence of homogeneity in allelic effects across
ancestry groups at the majority of previously reported lead SNPs argues against the
“synthetic association” hypothesis24. It is improbable that GWAS signals at most established
T2D susceptibility loci reflect unobserved lower frequency causal alleles with larger effects
because: (i) rare variants are unlikely to have arisen before human population migration out
of Africa and thus are not expected to be widely shared across diverse populations25; and (ii)
patterns of LD with these variants are anticipated to be highly variable between ethnicities.
To gain insights into the potential for the discovery of novel T2D susceptibility loci through
fixed-effects trans-ethnic meta-analysis, we next assessed the genome-wide coincidence of
risk alleles (i.e. direction of effect) across ancestry groups after exclusion of the 69
established autosomal GWAS signals, defined as mapping within 500kb of the previously
reported lead SNPs (Online Methods). First, we identified independent SNPs (separated by
at least 500kb) with nominal evidence of association (p≤0.001) with T2D from the European
ancestry meta-analysis. By aligning the effect of the T2D risk allele from the European
meta-analysis into the other ancestry groups, we observed evidence of significant excess in
directional concordance between ethnicities: 57.0% with East Asian populations (binomial
test p=0.0077); 55.4% with South Asian populations (binomial test p=0.032); and 56.6%
with Mexican and Mexican American populations (binomial test p=0.010). Using the same
approach, we also observed excess consistency in the direction of effect between ethnicities
at independent SNPs demonstrating weaker evidence of T2D association (0.001<p≤0.01)
from the European meta-analysis (Table 1). In contrast, when we considered independent
SNPs with no evidence of association (p>0.5) with T2D, there was no enrichment in
coincident risk alleles across ethnic groups. We repeated this analysis by identifying T2D
risk alleles at SNPs with nominal evidence of association in East Asian, South Asian, and
Mexican and Mexican American meta-analyses, in turn, and assessing concordance in the
direction of effect in each of the other ancestry groups (Supplementary Table 4). The
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evidence for an excess in concordance between T2D risk alleles across ethnicities was not as
strong, particularly for the Mexican and Mexican American meta-analysis. However, this
presumably reflects reduced power due to smaller sample sizes, and there was still
significant over representation of alleles with the same direction of effect across ancestry
groups at SNPs with nominal evidence of association with the disease.
Seven novel T2D susceptibility loci achieving genome-wide significance
The observations from our concordance analyses are consistent with a long tail of common
T2D susceptibility variants, with effects which are decreasing in magnitude, but which are
homogeneous across ancestry groups. Under such a model, we would expect these variants
to be amenable to discovery via trans-ethnic fixed-effects meta-analyses. In this study, by
aggregating the published ethnic-specific meta-analyses under a fixed-effects model, we
identified 33 independent SNPs (separated by at least 500kb) with suggestive evidence of
association (p<10−5) at loci not previously reported for T2D susceptibility in any ancestry
group (Supplementary Table 5, Supplementary Figure 1). By convention, we have labelled
loci according to the gene nearest to the lead SNP, unless a compelling biological candidate
mapped nearby. It is essential to validate partially imputed association signals with direct
genotyping. Consequently, we carried forward these 33 loci for in silico follow-up in a
meta-analysis of an additional 21,491 T2D cases and 55,647 controls of European ancestry5,
genotyped with the Metabochip (Online Methods, Supplementary Tables 1 and 2). This
custom array was designed to facilitate cost-effective replication of nominal associations for
T2D and other metabolic and cardiovascular traits26. However, it provides relatively limited
coverage of common genetic variation, genome-wide, with the result that the lead SNPs, or
close proxies (CEU r2>0.6 from Phase II HapMap), were present at just 24 of the loci. We
also identified poorer proxies at two additional loci, rs9505118 (SSR1/RREB1, CEU
r2=0.26, p=1.9×10−6) and rs4275659 (MPHOSPH9, CEU r2=0.48, p=5.5×10−6), which,
nonetheless, demonstrated only marginally weaker association signals than the lead SNPs
(SSR1/RREB1, rs9502570, p=5.7×10−7; MPHOSPH9, rs1727313, p=1.2×10−6). Given that
these variants met our threshold for follow-up from the trans-ethnic meta-analysis, they were
also considered for validation.
By combining association summary statistics from the trans-ethnic “discovery” and
European ancestry “validation” meta-analyses, SNPs achieved genome-wide significance
(combined meta-analysis p<5×10−8) at seven loci (Table 2, Figure 1). We observed no
evidence of heterogeneity in allelic effects between discovery and validation stages of the
combined meta-analysis (Supplementary Table 5). As expected, the novel loci are
characterised by lead SNPs that are relatively common in all ethnicities, and have modest
effects on T2D susceptibility which are homogeneous across ancestry groups
(Supplementary Table 6). Adjustments for covariates were not harmonised within or
between consortia because of variation in individual study design and recorded non-genetic
risk factors. However, we observed no evidence of heterogeneity in allelic effects in the
European ancestry validation meta-analysis after stratification of studies according to
covariate adjustment (Online Methods, Supplementary Table 7). These data thus provide no
evidence of bias in allelic effect estimates at lead SNPs at the novel loci, and suggest our
results to be robust to variability in correction for potential confounders across studies.
The novel loci include SNPs mapping near POU5F1/TCF19 in the major histocompatibility
complex (MHC), a region of the genome that is essential to immune response. The MHC
harbours HLA class II genes, which together account for approximately half the genetic risk
to type 1 diabetes (T1D)27. We observed no evidence of association of T2D with tags for
traditional T1D HLA risk alleles in the trans-ethnic meta-analysis: HLA-DR4 (rs660895,
p=0.32) and HLA-DR3 (rs2187668, p=0.34). Furthermore, when we considered lead SNPs at
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49 T1D susceptibility loci (Supplementary Table 8), we observed nominal evidence of
association (p<0.05) with T2D, with the same risk allele for both diseases, at just two
(GLIS3 and 6q22.32), but not at that mapping to the MHC (rs9268645, p=0.33). There is
very strong evidence that T1D-risk variants, particularly in the MHC, are also associated
with latent autoimmune diabetes of adulthood (LADA)28,29, a late-age onset, more indolent
form of the disease, which often results in a clinical misdiagnosis of T2D. Although studies
contributing to the trans-ethnic meta-analysis differed in the degree to which they were able
to exclude LADA cases, the lack of association of T1D-risk variants suggests that rates of
diagnostic misclassification of autoimmune diabetes were too modest to drive the T2D
GWAS signal at the POU5F1/TCF19 locus.
The novel loci also include SNPs mapping to ARL15 and SSR1/RREB1, which have been
previously implicated, at genome-wide significance, in regulation of fasting insulin (FI) and
fasting glucose (FG), respectively30. The lead SNPs for T2D (rs702634) and FI (rs4865796)
mapping to ARL15 are closely correlated in European and East Asian ancestry populations
(CEU r2=1.00 and CHB+JPT r2=0.87 from Phase II HapMap). However, the lead T2D SNP
(rs9505118) is independent of that for FG (rs17762454) at the SSR1/RREB1 locus (CEU and
CHB+JPT r2<0.05). The ARL15 locus has also been associated with circulating adiponectin
levels, an adipocyte-secreted protein that has anti-diabetic effects31, but the lead SNP
(rs4311394) is independent of that for T2D susceptibility from the trans-ethnic meta-
analysis.
To obtain a more comprehensive view of the overlap of novel T2D susceptibility loci with
metabolic phenotypes, we interrogated published European ancestry meta-analyses from the
Meta-Analysis of Glycaemic and Insulin-related Consortium (MAGIC) Investigators3,30, the
Genetic Investigation of ANthropometric Traits (GIANT) Consortium32,33 and the Global
Lipids Genetics Consortium34, to evaluate the effect of T2D risk alleles on: glycaemic traits,
including homeostatic model of assessment indices of beta-cell function (HOMA-B) and
insulin resistance (HOMA-IR); anthropometric measures; and plasma lipid concentrations
(Online Methods, Supplementary Tables 9, 10 and 11). T2D risk alleles at SSR1/RREB1
and LPP have features that indicate a primary role on susceptibility through beta-cell
dysfunction: increased FG (p=1.0×10−5 and p=8.6×10−7, respectively), and reduced
HOMA-B (p=0.11 and p=0.011, respectively). Conversely, the T2D risk allele mapping to
ARL15 is associated with increased FI, most strongly after adjustment for body-mass index
(BMI) (p=5.0×10−12), and increased HOMA-IR (p=0.021), and is thus more characteristic of
action through insulin resistance. This risk allele is also associated with reduced high-
density lipoprotein cholesterol (p=0.022) and increased triglycerides (p=0.010), as expected,
but also with reduced BMI (p=5.6×10−5).
To identify the most promising functional candidate transcripts amongst those mapping to
the novel susceptibility loci, we interrogated public databases and unpublished resources for
expression quantitative trait loci (eQTL) from a variety of tissues (Online Methods). The
lead T2D SNPs at three loci showed nominal association (p<10−5) with expression, and
were in strong LD (CEU and CHB+JPT r2>0.8) with the reported cis-eQTL variant: SSR1
(B cells, p=2.2×10−6) at the SSR1/RREB1 locus; ABCB9 (liver, p=7.4×10−12) and SETD8
(lung, p<2.0×10−16) at the MPHOSPH9 locus; and HCG27 (monocytes, p=1.3×10−69) at the
POU5F1/TCF19 locus (Supplementary Table 12).
We also evaluated novel loci for potential functional mechanisms underlying T2D
susceptibility (Online Methods). We identified variants in pilot data from the 1000
Genomes Project25 that are in strong LD (CEU and CHB+JPT r2>0.8) with the lead SNPs in
the seven novel susceptibility loci for functional annotation. We identified a missense
variant at the POU5F1/TCF19 locus in TCF19 (rs113581344, V211M; CEU r2=0.96 and
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CHB+JPT r2=0.80 with lead SNP rs3130501), although it is predicted to be tolerated by
SIFT35 (Supplementary Table 13). Lead SNPs in the novel susceptibility loci were also in
strong LD with variants in the untranslated regions of SSR1 (at the SSR1/RREB1 locus) and
ABCB9, OGFOD2, and PITPNM2 (at the MPHOSPH9 locus). Variants in strong LD with
the lead SNPs at two of the novel susceptibility loci overlap regions of predicted regulatory
function generated by the ENCODE Project36 (Supplementary Figure 2). The lead SNP at
the LPP locus maps to an enhancer region which is active in HepG2 cells. We also identified
a variant at the FAF1 locus (rs58836765; CEU r2=0.89 and CHB+JPT r2=0.80 with lead
SNP rs17106184) which overlaps a region of open chromatin activity in pancreatic islets and
other cell types. This open chromatin site is in a region correlated with expression of
ELAVL4, which has been demonstrated to regulate insulin translation in pancreatic beta
cells37, highlighting this transcript as a credible candidate at the FAF1 locus. Regulatory
annotations in HepG2 cells and pancreatic islets are both broadly enriched at T2D associated
variants38, and are thus supportive of these functional mechanisms for causal variant activity
at both loci.
Improved fine-mapping resolution at T2D susceptibility loci
Given our observation that the causal variants underlying GWAS signals are shared across
ancestry groups at many T2D susceptibility loci, we evaluated the evidence for improved
fine-mapping resolution through trans-ethnic meta-analysis. For this purpose, we combined
association summary statistics from the ethnic-specific meta-analyses using MANTRA39.
This Bayesian approach has the advantage of allowing for heterogeneity in allelic odds-
ratios between ancestry groups, arising as a result of differential patterns of LD with a
shared underlying causal variant across diverse populations, which cannot be accommodated
in fixed-effects meta-analysis (Online Methods). Simulation studies have demonstrated
improved detection and localisation of causal variants through trans-ethnic meta-analysis
with MANTRA compared to either a fixed- or random-effects model39,40.
Within each locus, we constructed “credible sets”41 of SNPs that are most likely to be causal
based on their statistical evidence of association from the MANTRA meta-analysis. Credible
sets can be interpreted in a similar way to confidence intervals in a frequentist statistical
framework. For example, assuming that a locus harbours a single causal variant that is
reported in the meta-analysis, the probability that it will be contained in the 99% credible set
is 0.99. Smaller credible sets, in terms of the number of SNPs they contain, or the genomic
interval they cover, thus correspond to fine-mapping at higher resolution. It is essential that
SNP coverage is as uniform as possible across studies in the construction of credible sets.
Otherwise, differences in association signals between variants may reflect variability in
sample sizes in the meta-analysis, and not true differences in magnitude of effects on T2D
susceptibility. Consequently, we have not considered the European ancestry Metabochip
validation studies in our fine-mapping analyses because SNP density on the array is too
sparse, across the majority of T2D susceptibility loci, to allow high-quality imputation up to
the Phase II/III HapMap reference panels utilised in the trans-ethnic discovery GWAS.
In constructing credible sets, we assume that there is a single causal variant at each locus.
However, there is increasing evidence that multiple association signals, typically
characterised by independent common “index” SNPs, are relatively widespread at T2D
susceptibility loci, for example CDKN2A/B and KCNQ16. Fine-mapping of these
independent association signals will require formal conditioning, adjusting for genotypes at
each index SNP in turn, before construction of the credible set for each underlying causal
variant. Approximate conditioning, without formal computation, as implemented in
GCTA42, makes use of meta-analysis summary statistics and a reference panel to
approximate LD between SNPs (and hence correlation between parameter estimates in a
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joint association model). Unfortunately, this approach is not feasible in a trans-ethnic
context because of differences in LD structure between ancestry groups, and thus could not
be applied in this study. Consequently, the credible sets defined here correspond to fine-
mapping across association signals at each locus.
To assess the improvements in fine-mapping resolution by combining GWAS from diverse
populations, we compared the properties of the MANTRA 99% credible set on the basis of
association summary statistics from: (i) the European ancestry only meta-analysis; and (ii)
the trans-ethnic meta-analysis of European, East Asian, South Asian, and Mexican and
Mexican American ancestry groups. We focussed on ten autosomal loci (of the 69
previously established) that attained association with T2D susceptibility at genome-wide
significance in the European ancestry meta-analysis (Table 3). We did not consider loci with
weaker signals of association since they were typically characterised by large 99% credible
sets in the European ancestry meta-analysis, and thus might provide an over-estimate of the
improvement in fine-mapping resolution by combining GWAS across ancestry groups. Of
the loci considered, only at MTNR1B, did we not see any improvement in fine-mapping
resolution, in terms of the number of SNPs and the genomic interval covered by the 99%
credible set after trans-ethnic meta-analysis.
The greatest enhancement in fine-mapping resolution after trans-ethnic meta-analysis was
observed at the JAZF1 locus, where the genomic interval covered by the 99% credible set
was reduced from 76kb to just 16kb (Figure 2, Supplementary Figure 3). Of the nine
variants in the European 99% credible set, five were excluded after trans-ethnic meta-
analysis because of low LD with the lead SNP at this locus in East Asian ancestry
populations (CHB+JPT r2<0.05 with rs864745). Amongst the variants retained in the 99%
credible set after trans-ethnic meta-analysis, interrogation of predicted regulatory function
from the ENCODE Project36 revealed that rs1635852 maps to a region of open chromatin
with enhancer activity, bound by several transcription factors. This SNP has been previously
shown to have allelic differences in pancreatic islet enhancer activity43, and is also
correlated with expression of CREB5, highlighting this transcript as a credible candidate at
the JAZF1 locus.
We also observed a substantial reduction in the genomic interval covered by the credible set
at the SLC30A8 locus (Figure 2, Supplementary Figure 3), from 35kb (four SNPs) on the
basis of only European ancestry GWAS, to less than 1kb (two SNPs) after trans-ethnic meta-
analysis. However, the lead SNP is strongly correlated with all variants in the credible set
before trans-ethnic meta-analysis in both European and East Asian ancestry groups (CEU
and CHB+JPT r2≥0.8 with rs13266634), suggesting that the improved fine-mapping
resolution at this locus is more likely due to increased sample size than differences in LD
structure between the populations. Encouragingly, the lead SNP after trans-ethnic meta-
analysis is more clearly separated from others in the credible set, and is a non-synonymous
variant, R325W, which plays an established functional role in T2D susceptibility44.
Finally, we tested variants present in the 99% credible sets at the ten loci, on the basis of
only the European ancestry GWAS and the trans-ethnic meta-analysis, for enrichment of
functional annotation compared to randomly shifted element locations (Online Methods).
Variants in the trans-ethnic 99% credible sets were significantly enriched (empirical p<0.05)
for overlap with DNaseI hypersensitive sites (DHS p=0.038) and transcription factor binding
sites (TFBS p=0.0060). However, no such enrichment in either annotation category was
observed for the European ancestry 99% credible sets (DHS p=0.18; TFBS p=0.087). These
data suggest that variants retained after trans-ethnic meta-analysis show greater potential for
functional impact on T2D susceptibility through these regulatory mechanisms.
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The fine-mapping intervals defined by credible sets after trans-ethnic meta-analysis are
limited by the density and allele frequency spectrum of the GWAS genotyping arrays and
HapMap reference panels used for imputation. Although these reference panels provide
comprehensive coverage of common SNPs (MAF>5%) across ancestry groups, imputation
up to phased haplotypes from the 1000 Genomes Project25,45, for example, would allow
assessment of the impact of lower frequency variation on T2D susceptibility in diverse
populations46–48. However, we have demonstrated that, for a fixed reference panel, trans-
ethnic meta-analysis can improve localisation of common causal SNPs within established
T2D susceptibility loci, and have identified highly annotated variants within fine-mapping
intervals defined by the 99% credible sets. We have also assessed the sensitivity of the trans-
ethnic fine-mapping analysis to genotype quality at directly typed or imputed SNPs
(Supplementary Table 14). We repeated MANTRA fine-mapping with subsets of SNPs that
pass quality control in at least 80% (N=88,361) or 90% (N=99,406) of individuals from the
trans-ethnic meta-analysis. As the threshold for reported sample size increased, the number
of SNPs included in the fine-mapping analysis was reduced, but the genomic intervals
covered by the 99% credible sets remained unchanged, suggesting resolution to be relatively
robust to genotype quality at common variants.
DISCUSSION
We have identified seven novel loci for T2D susceptibility at genome-wide significance by
combining GWAS from multiple ancestry groups. Our study has provided evidence of many
more common variant loci, not yet reaching genome-wide significance, which contribute to
the “missing heritability” of T2D susceptibility, in agreement with polygenic analyses in
European ancestry GWAS5,49. The effects of these common variants are modest, but
homogeneous across ancestry groups, and thus would be amenable to discovery through
trans-ethnic meta-analysis in larger samples. We have also demonstrated improvements in
the resolution of fine-mapping of common variant association signals through trans-ethnic
meta-analysis, even in the absence of GWAS of African ancestry, which would be expected
to better refine localisation due to reduced LD in these populations. Future releases of
reference panels from the 1000 Genomes Project are anticipated to include 2,500 samples,
including haplotypes of South Asian ancestry and wider representation of African descent
populations. This panel will provide a comprehensive catalogue of genetic variation with
MAF as low as 0.5%, as well as many rarer variants, across major ancestry groups, thus
facilitating imputation and coverage of loci for future trans-ethnic fine-mapping efforts.
Our analyses clearly highlight the benefits of combining GWAS from multiple ancestry
groups for discovery and characterisation of common variant loci contributing to complex
traits, and emphasise an exciting opportunity to further our understanding of the biological
mechanisms underlying human diseases across populations from diverse ethnicities.
ONLINE METHODS
Ancestry-specific GWAS meta-analyses
Ancestry-specific meta-analyses have been previously performed by: the DIAGRAM
Consortium (12,171 cases and 56,862 controls, European ancestry)5; the AGEN-T2D
Consortium (6,952 cases and 11,865 controls, East Asian ancestry)11; the SAT2D
Consortium (5,561 cases and 14,458 controls, South Asian ancestry)13; and the MAT2D
Consortium (1,804 cases and 779 controls, Mexican and Mexican American ancestry)15.
Further details of the samples and methods employed within each ancestry group are
presented in the corresponding consortium papers5,11,13,15. Briefly, individuals were assayed
with a range of genotyping products, with sample and SNP quality control (QC) undertaken
within each individual study (Supplementary Tables 1 and 2). Each GWAS scaffold was
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imputed up to 2.5 million autosomal SNPs using reference panels from Phase II/III
HapMap22,23 (Supplementary Table 2). Each SNP with MAF>1%, (except MAF>5% in the
Mexican and Mexican American ancestry GWAS due to smaller sample size), and passing
QC, was tested for association with T2D under an additive model after adjustment for study-
specific covariates (Supplementary Table 2). Covariate adjustments were not harmonised
within or between consortia because of variation in individual study design and recorded
non-genetic risk factors. The results of each GWAS were corrected for population structure
with genomic control50 (unless λGC<1). Association summary statistics from GWAS within
each ancestry group were then combined via fixed-effects meta-analysis. The results of each
ancestry meta-analysis were then corrected by a second round of genomic control: European
ancestry (λGC=1.10); East Asian ancestry (λGC=1.05); South Asian ancestry (λGC=1.02);
Mexican and Mexican American ancestry (λGC=1.01).
Trans-ethnic “discovery” GWAS meta-analysis
Association summary statistics from each ancestry-specific meta-analysis were combined
via fixed-effects inverse-variance weighted meta-analysis(in a total of 26,488 cases and
83,964 controls). The association results of the trans-ethnic meta-analysis were corrected by
genomic control50 (λGC=1.05).
Heterogeneity analyses
For each previously reported lead SNP at an established T2D susceptibility locus, we
assessed heterogeneity in allelic effects between the ethnic-specific meta-analyses by means
of Cochran’s Q-statistic51 (Supplementary Table 3). Amongst the 52 SNPs passing QC in all
four ethnic-specific meta-analyses, we identified those that showed the same direction of
effect across all ancestry groups, and evaluated the significance of the excess in concordance
(12.5% expected) with a one-sided binomial test.
Concordance analyses
We identified SNPs passing QC and with MAF>1% in all four ethnic-specific meta-
analyses. We excluded variants in the 69 established autosomal T2D susceptibility loci,
defined as 500kb up- and down-stream of the previously reported lead SNPs. We also
excluded AT/GC SNPs to eliminate bias due to strand misalignment between ethnic-specific
meta-analyses. Amongst the remaining SNPs, we selected an independent subset with
nominal evidence of association (p≤0.001) with T2D from the European ancestry meta-
analysis, separated by at least 500kb. For each independent SNP, we identified the T2D risk
allele from the European ancestry meta-analysis and determined the direction of effect in the
East Asian, South Asian, and Mexican and Mexican American ancestry meta-analyses. We
calculated the proportion of these SNPs that had the same direction of effect for the
European ancestry risk allele and the significance of the excess in concordance (50%
expected) with a one-sided binomial test. We repeated this analysis for SNPs with weaker
evidence of association with T2D from the European ancestry meta-analysis: 0.001<p≤0.01;
0.01<p≤0.5; and 0.5<p≤1 (Table 1). Finally, we repeated these analyses, using the East
Asian, South Asian, and Mexican and Mexican American ancestry meta-analyses, in turn, to
identify subsets of independent T2D risk alleles, and assessed concordance into the other
ethnic groups (Supplementary Table 4).
European ancestry “validation” meta-analysis
The previously published validation meta-analysis consisted of 21,491 cases and 55,647
controls of European ancestry from the DIAGRAM Consortium5, all genotyped with the
Metabochip26 (Supplementary Table 1). We excluded the Pakistan Risk Of Myocardial
Infarction Study (PROMIS) from the validation meta-analysis to avoid overlap with a subset
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of the same individuals contributing to the SAT2D Consortium meta-analysis13. Full details
of the samples and methods employed in the validation meta-analysis are presented in the
DIAGRAM Consortium paper5. Briefly, sample and SNP QC were undertaken within each
study (Supplementary Table 2). Each high-quality SNP (MAF>1%) was tested for
association with T2D under an additive model after adjustment for study-specific covariates
(Supplementary Table 2). Association summary statistics for each study were corrected
using the genomic control inflation factor obtained from a subset of 3,598 “QT interval”
replication SNPs5,26 (unless λQT<1). These statistics were then combined via fixed-effects
inverse-variance weighted meta-analysis, and were corrected by a second round of genomic
control (λQT=1.19).
Combined meta-analysis
We selected lead SNPs at 33 novel loci with suggestive evidence of association (p<10−5)
from the trans-ethnic “discovery” GWAS meta-analysis for in silico follow-up in the
European ancestry “validation” meta-analysis. Of these, 16 SNPs were genotyped directly
on Metabochip, and 10 more had a proxy (CEU and CHB+JPT HapMap r2≥0.2). For these
26 SNPs, association summary statistics from the discovery and validation meta-analyses
were combined via fixed-effects inverse-variance weighted meta-analysis (Supplementary
Table 5). The combined meta-analysis consisted of 47,979 T2D cases and 139,611 controls.
Heterogeneity in allelic effects between the two stages of the combined meta-analysis was
assessed by means of Cochran’s Q-statistic51.
Sensitivity to covariate adjustment
We identified 19 studies (11,327 cases and 31,342 controls) from the European ancestry
“validation” meta-analysis that adjusted for only age, sex (unless male- or female-specific),
and population structure, where necessary (Supplementary Table 2): AMC-PAS; BHS;
DILGOM; EAS; EGCUT; EMIL-ULM; EPIC; FUSION Stage 2; D2D2007; Dr’s Extra;
HUNT; METSIM (male-specific); HNR, IMPROVE; KORAGen Stage 2; PIVUS;
THISEAS; ULSAM (male-specific); and WARREN2. Association summary statistics from
each of these studies were then combined via fixed-effects inverse-variance weighted meta-
analysis, the results of which were subsequently corrected for genomic control (λQT=1.12).
The remaining six studies (10,164 cases and 24,305 controls) did not adjust for age and/or
sex, or included additional covariates to account for BMI or cardiovascular-related disease
status (Supplementary Table 2): deCODE Stage 2; DUNDEE; GMetS; PMB;
SCARFSHEEP; and STR. Association summary statistics from each of these studies were
then combined via fixed-effects inverse-variance weighted meta-analysis, but did not require
subsequent correction for genomic control (λQT=1.00). We then tested for heterogeneity in
allelic effects between these two sets of studies by means of Cochran’s Q-statistic51
(Supplementary Table 7).
Association of lead T1D SNPs with T2D
We obtained association summary statistics with T2D from the trans-ethnic meta-analysis
for previously reported lead SNPs in established T1D susceptibility loci27 (Supplementary
Table 8). For each SNP, we aligned the allelic effect on T2D according to the risk allele for
T1D (where reported). We also obtained association summary statistics for tags for T1D
HLA risk alleles: HLA-DR4 (rs660895) and HLA-DR3 (rs2187668).
Association of lead T2D SNPs with metabolic traits
We obtained association summary statistics (p-values, directed Z-scores and/or allelic effects
and corresponding standard errors) for lead SNPs at novel T2D susceptibility loci in
published European ancestry GWAS meta-analyses of metabolic phenotypes: glycaemic
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traits3,30, anthropometric measures32,33, and plasma lipid concentrations34. We considered
glycaemic traits in non-diabetic individuals from the MAGIC Investigators (Supplementary
Table 9). For FG and FI concentrations (with and without adjustment for BMI), the meta-
analysis consisted of up to 133,010 and 108,557 individuals, respectively. For HOMA-B and
HOMA-IR, the meta-analysis consisted of up to 37,037 individuals. We considered
anthropometric measures from the GIANT Consortium (Supplementary Table 10). For BMI
and waist-hip ratio adjusted for BMI, the meta-analysis consisted of 123,865 and 77,167
individuals, respectively. Finally, we considered plasma lipid concentrations from the
Global Lipids Genetics Consortium (Supplementary Table 11). For total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides, the
meta-analysis consisted of up to 100,184 individuals.
Expression analyses
We interrogated public databases and unpublished resources for cis-eQTL expression with
lead SNPs in the novel susceptibility loci in multiple tissues. Details of these resources are
summarised in the Supplementary Note. The collated results from these resources met study-
specific criteria for statistical significance for association with expression. For each
transcript associated with the lead T2D SNP (Supplementary Table 12), we identified the
cis-eQTL SNP with the strongest association with expression in the same tissue, and
subsequently estimated the LD between them, using pilot data from the 1000 Genomes
Project25 (CEU and CHB+JPT) to assess coincidence of the signals.
Functional annotation
We identified variants in pilot data from the 1000 Genomes Project25 that are in strong LD
(CEU and CHB+JPT r2>0.8) with the lead SNPs in the novel susceptibility loci for
functional annotation. Identified non-synonymous variants were interrogated for likely
downstream functional consequences using SIFT35 (Supplementary Table 13). Variants
were also assessed for overlap with regions of predicted regulatory function generated by the
ENCODE Project36 including: ChromHMM regulatory state definitions from 9 cell lines
(GM12878, HepG2, HUVEC, HMEC, HSMM, K562, NHLF, NHEK, and hESC);
transcription factor binding ChIP sites from 95 cell types; open chromatin (DNaseI
hypersensitivity) sites from 125 cell types; transcripts correlated with open chromatin site
activity; and sequence motifs from JASPAR, TRANSFAC and de novo prediction
(Supplementary Figure 2).
Fine-mapping analyses
We used MANTRA39 to fine-map T2D susceptibility loci on the basis of association
summary statistics from: (i) the meta-analysis of European ancestry GWAS only5; and (ii)
the trans-ethnic meta-analysis of European, East Asian, South Asian, and Mexican and
Mexican American ancestry GWAS5,11,13,15. MANTRA allows for trans-ethnic
heterogeneity in allelic effects, arising as a result of differences in the structure of LD with
the causal variant in diverse populations, by assigning ancestry groups to “clusters”
according to a Bayesian partition model of relatedness between them, defined by pair-wise
genome-wide mean allele frequency differences (Supplementary Figure 4). Evidence in
favour of association of each SNP with T2D is measured by a Bayes’ factor (BF). We
assume a single causal variant for T2D at each locus (defined by the region 500kb up- and
down-stream of the lead SNP from the trans-ethnic meta-analysis). We then calculated the
posterior probability that the jth SNP is causal, amongst those reported in the meta-analysis,
by:
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In this expression, BFj denotes the BF in favour of association of the jth SNP, and the
summation in the denominator is over all variants passing QC across the locus41. A 99%
credible set of variants was then constructed by: (i) ranking all SNPs according to their BF;
and (ii) combining ranked SNPs until their cumulative posterior probability exceeds 0.99.
SNPs in the 99% credible sets were assessed for enrichment in ChromHMM regulatory state
(enhancer, promoter and insulator), DNaseI hypersensitive and transcription factor binding
sites, using data from the ENCODE Project36. We performed 1,000 permutations by shifting
the location of the annotation sites a random distance within 100kb, and recalculated the
overlap to obtain empirical p-values for enrichment in each annotation category.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Signal plots of the trans-ethnic “discovery” GWAS meta-analysis for novel T2D
susceptibility loci
The trans-ethnic meta-analysis comprises 26,488 T2D cases and 83,964 controls from
populations of European, East Asian, South Asian, and Mexican and Mexican American
ancestry, imputed up to 2.5 million Phase II/III HapMap autosomal SNPs. Each point
represents a SNP passing quality control in the trans-ethnic meta-analysis, plotted with their
p-value (on a −log10 scale) as a function of genomic position (NCBI Build 36). In each
panel, the lead SNP is represented by the purple symbol. The colour coding of all other
SNPs indicates LD with the lead SNP (estimated by CEU r2 from Phase II HapMap): red
r2≥0.8; gold 0.6≤r2<0.8; green 0.4≤r2<0.6; cyan 0.2≤r2<0.4; blue r2<0.2; grey r2 unknown.
The shape of the plotting symbol corresponds to the annotation of the SNP: upward triangle
for framestop or splice; downward triangle for non-synonymous; square for synonymous or
UTR; and circle for intronic or non-coding. Recombination rates are estimated from Phase II
HapMap and gene annotations are taken from the University of California Santa Cruz
genome browser.
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Figure 2. Signal plots presenting 99% credible sets of SNPs at the JAZF1 and SLC30A8 loci
The credible sets were constructed on the basis of: (i) the meta-analysis of European
ancestry GWAS only (12,171 cases and 56,862 controls); and (ii) the trans-ethnic meta-
analysis of European, East Asian, South Asian, and Mexican and Mexican American
ancestry GWAS (26,488 cases and 83,964 controls). In each panel, each point represents a
SNP passing quality control in the MANTRA analysis, plotted with their Bayes’ factor (on a
log10 scale) as a function of genomic position (NCBI Build 36). The lead SNP is represented
by the purple symbol. The colour coding of all other SNPs indicates LD with the lead SNP
(estimated by Phase II HapMap CEU r2 for the European ancestry meta-analysis and CHB
+JPT for the trans-ethnic meta-analysis to highlight differences in structure between
ancestry groups): red r2≥0.8; gold 0.6≤r2<0.8; green 0.4≤r2<0.6; cyan 0.2≤r2<0.4; blue
r2<0.2; grey r2 unknown. The shape of the plotting symbol corresponds to the annotation of
the SNP: upward triangle for framestop or splice; downward triangle for non-synonymous;
square for synonymous or UTR; and circle for intronic or non-coding. Recombination rates
are estimated from Phase II HapMap and gene annotations are taken from the University of
California Santa Cruz genome browser. The genomic region covered by the 99% credible
set is highlighted in grey.
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